Nedaplatin: a radiosensitizing agent for patients with cervical cancer
Loading...
Authors
Mabuchi, Seiji
Kimura, Tadashi
Issue Date
2010-09-21
Type
Article
Language
en_US
Keywords
Nedaplatin , Radiosensitizing Agent , Patients with Cervical Cancer
Alternative Title
Abstract
Despite the recent advances in the management of cervical cancer using cisplatin-based concurrent chemoradiotherapy, substantial treatment failure still occurs, especially in advanced-stage patients and early-stage cervical cancer patients with high-risk prognostic factors. Therefore, efforts to further improve the survival and quality of life of these patients are necessary. Nedaplatin (cis-diammine-glycoplatinum), a derivative of cisplatin, was developed with the aim of producing a treatment with a similar effectiveness to cisplatin but decreased renal and gastrointestinal toxicities. Based on the promising results of preclinical studies, the clinical efficacy of nedaplatin as a radiosensitizing agent was evaluated in patients with cervical cancer. Retrospective analysis of nedaplatin-based concurrent chemoradiotherapy (CCRT) against cervical cancer suggested that nedaplatin-based CCRT can be considered as an alternative to cisplatin-based CCRT in both early-stage and advanced-stage cervical cancer patients. However, due to the lack of a randomized controlled study, nedaplatin-based CCRT has not been convincingly proven to be clinically effective in patients with cervical cancer. Further investigations in randomized controlled trials are therefore needed.
Description
Citation
Mabuchi, S., & Kimura, T. (2011). Nedaplatin: a radiosensitizing agent for patients with cervical cancer. Chemotherapy research and practice, 2011, 963159. https://doi.org/10.1155/2011/963159
Publisher
Chemotherapy Research and Practice